Stéphane Gennai | Medicine and Health Sciences | Innovative Research Award

Published on by Top Teachers

Innovative Research Award

Stéphane Gennai
Researcher, University of Reims Champagne-Ardenne (Reims University Hospital), France

Stéphane Gennai
Affiliation University of Reims Champagne-Ardenne (Reims University Hospital)
Country France
Scopus ID 23093862000
Documents 55
Citations 1,267
h-index 14
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0002-8490-4706

Stéphane Gennai is a French emergency medicine physician and university professor affiliated with the University of Reims Champagne-Ardenne and the Reims University Hospital. His research focuses on emergency care, infectious diseases, inflammatory biomarkers, and prehospital management of critically ill patients [1]. He has authored 55 documents indexed in Scopus, accumulating 1,267 citations and an h-index of 14 [2]. His work has contributed to clinical decision-making in emergency departments and the management of SARS-CoV-2 patients [7].

Abstract

This article examines the academic and clinical contributions of Stéphane Gennai, Professor of Universities – Hospital Practitioner at the University of Reims Champagne-Ardenne and the Reims University Hospital. His research addresses emergency medicine, infectious disease management, inflammatory biomarker prescriptions, and prehospital critical care [1]. With 55 Scopus-indexed documents, 1,267 citations, and an h-index of 14, his scholarly output supports evidence-based emergency practice [2]. His contributions have informed clinical decision-making, particularly in the management of SARS-CoV-2 patients and the use of risk-stratification models [7].

Keywords

  • Emergency Medicine, Inflammatory Biomarkers, SARS-CoV-2, Prehospital Care, Clinical Decision-Making, Antibiotic Prescriptions

Introduction

Stéphane Gennai is a prominent figure in French emergency medicine, currently serving as Head of the Emergency and Unscheduled Care Department at the Reims University Hospital since 2023 [1]. He has been affiliated with INSERM Unit UMR-S 1250 (Pulmonary Pathologies and Cellular Plasticity – P3Cell) since 2021 and has held the position of University Coordinator for Emergency Medicine in Champagne-Ardenne since 2019 [2]. His career spans clinical practice, research, and teaching, with a strong focus on improving emergency care through evidence-based research [3].

Research Profile

Stéphane Gennai’s research profile is characterized by a multidisciplinary approach, integrating emergency medicine with infectious diseases, epidemiology, and critical care. He obtained his Habilitation to Supervise Research (HDR) in 2021 and has been a PU-PH since 2022 [1]. His Scopus record includes 55 documents, 1,267 citations, and an h-index of 14, reflecting sustained scholarly impact in Medicine and Health Sciences [2]. He is also a member of the CPD Commission of the French Society of Emergency Medicine and Vice-President of the Grand Est College of Emergency Medicine [3].

Research Contributions

Stéphane Gennai has made significant contributions to emergency medicine research, particularly in the areas of inflammatory biomarker prescriptions, management of transient ischemic attacks, and prehospital care of critically ill patients [4]. His work on the revised HOME-CoV score has provided a risk-stratification model for patients with probable or proven COVID-19 in emergency departments [7]. He has also collaborated on studies evaluating osteopathic treatment for ankle sprains and the use of high-speed trains for mass transfers of critically ill patients [3] [4].

Publications

Stéphane Gennai’s publication record includes numerous peer-reviewed articles in high-impact journals. Notable contributions include the TRANSCOV cohort study on high-speed trains versus air transport for mass transfers of critically ill patients [3], and a study on early osteopathic treatment for acute lateral ankle sprains [4]. His work on smartphone dispatch applications for out-of-hospital cardiac arrest and the BASCULE study on triage in emergency departments further demonstrates his commitment to improving emergency care [5] [6].

Research Impact

The impact of Gennai’s research is evidenced by 1,267 citations and an h-index of 14, indicating that his work is frequently referenced by peers in emergency medicine and related fields [2]. His contributions to the management of SARS-CoV-2 in emergency departments have influenced clinical practice and policy, particularly through the validation of the HOME-CoV score [7]. His research on inflammatory biomarkers has also informed antibiotic stewardship and diagnostic strategies [1].

Award Suitability

Given his extensive research output, clinical leadership, and contributions to emergency medicine, Stéphane Gennai is a strong candidate for the Innovative Research Award at the Top Teachers Awards. His work has advanced the understanding and management of critical conditions in emergency settings, with measurable impact on patient care and clinical decision-making [1] [2]. His dedication to teaching and supervision further underscores his suitability for this recognition [3].

Conclusion

Stéphane Gennai’s career reflects a sustained commitment to advancing emergency medicine through rigorous research, clinical excellence, and education. His Scopus-recorded 55 documents, 1,267 citations, and h-index of 14 attest to his scholarly impact [2]. His contributions to the management of SARS-CoV-2, inflammatory biomarkers, and prehospital care have informed practice and policy, making him a deserving recipient of the Innovative Research Award [7].

References

  1. Elsevier. (n.d.). Scopus author details: Stéphane Gennai, Author ID 23093862000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=23093862000
  2. ORCID. (n.d.). Stéphane Gennai ORCID profile. ORCID.
    https://orcid.org/0000-0002-8490-4706
  3. Thipayamaskomon, C., Grimaud, O., Tattevin, P., Lamhaut, L., Leray, E., Letellier, N., Bayat, S., et al. (2026). High-speed trains versus air transport vectors for mass transfers of critically ill patients: The TRANSCOV cohort study. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0348090
  4. Bournon, C., Prin-Conti, D., Douay, J., Montfajon, P. A., Kanagaratnam, L., & Gennai, S. (2026). Early osteopathic treatment delivered to patients with an acute lateral ankle sprain improves recovery: An investigative study. Journal of Osteopathic Medicine.
    DOI: https://doi.org/10.1515/jom-2025-0096
  5. Soumagnac, T., Soumagnac, M. T., Raphalen, J. H., Hutin, A., Lamhaut, L., Bossaert, C., Dolveck, F., et al. (2025). What to expect from a smartphone dispatch application for out-of-hospital cardiac arrest in a national population? Resuscitation.
    DOI: https://doi.org/10.1016/j.resuscitation.2025.110887
  6. Bilbault, P., Bronner, C., Etienne, A., Goudour, J., Dagtekin, S., Maire, B., Gennai, S., Chouihed, T., et al. (2025). BASCULE study: Is it possible to refer patients after triage in an emergency department to community medicine from a capacity standpoint for general medicine? Annales Françaises de Médecine d’Urgence.
    DOI: https://www.jle.com/10.1684/afmu.2025.0694
  7. Douillet, D., Riou, J., Morin, F., Mahieu, R., Chauvin, A., Gennai, S., Ferrant, L., Lopez, R., Sebbane, M., et al. (2024). Derivation and validation of a risk-stratification model for patients with probable or proven COVID-19 in EDs: The revised HOME-CoV score. Emergency Medicine Journal, 41(4), 218–225.
    DOI: https://doi.org/10.1136/emermed-2022-212805

Ailazzat Aitkenova | Pharmaceutical Technology | Best Research Article Award

Published on by Top Teachers

Best Research Article Award

Ailazzat Aitkenova
Karaganda Medical University, Kazakhstan
Ailazzat Aitkenova
Affiliation Karaganda Medical University
Country Kazakhstan
Scopus ID 58637239800
Documents 2
Citations 7
h-index 1
Subject Area Pharmaceutical Technology
Event Top Teachers Awards
ORCID 0000-0002-0851-866X

Ailazzat Aitkenova is a pharmaceutical researcher and academic affiliated with Karaganda Medical University, Kazakhstan. Her scholarly activities are centered on pharmacognosy, medicinal plants, pharmaceutical production technology, and the scientific development of plant-derived therapeutic formulations. As a third-year PhD doctoral student and Assistant Professor, she contributes to academic research focused on phytochemical investigations, pharmaceutical standardization, and innovative transdermal drug delivery systems.[1]

Her research activities emphasize evidence-based pharmaceutical science through the integration of phytochemical screening, GC–MS analysis, chromatographic methods, and formulation science. Particular scientific attention has been devoted to species belonging to the genus Iris, including their phytochemical composition, morphological characteristics, and therapeutic potential in pharmaceutical applications.[2]

Abstract

This article presents an academic overview of the scientific profile and research contributions of Ailazzat Aitkenova in the field of pharmaceutical sciences and pharmaceutical production technology. Her work primarily focuses on pharmacognosy, medicinal plants, phytochemical characterization, pharmaceutical formulation development, and natural-product-based therapeutic innovation. Through the application of analytical techniques such as gas chromatography–mass spectrometry (GC–MS) and chromatographic analysis, her research contributes to the identification and evaluation of biologically active compounds of pharmaceutical significance.[2]

Her investigations involving medicinal plant species of the genus Iris support the advancement of evidence-based natural medicine and pharmaceutical standardization. Additionally, her work in transdermal drug delivery systems and soft dosage form development demonstrates interdisciplinary integration between phytochemistry and pharmaceutical technology. These activities collectively support contemporary pharmaceutical innovation and the development of natural-product-based therapeutic systems.[3]

Keywords

  • Pharmaceutical Technology
  • Pharmacognosy
  • Medicinal Plants
  • Phytochemical Analysis
  • GC–MS Analysis
  • Transdermal Drug Delivery
  • Natural Products
  • Herbal Formulations
  • Chromatographic Methods
  • Medicinal Plant Standardization

Introduction

Pharmaceutical research involving medicinal plants has gained increasing importance within modern evidence-based healthcare systems due to the growing demand for biologically active natural compounds and sustainable therapeutic development. Scientific advancements in phytochemistry and pharmaceutical production technology have enabled researchers to explore plant-derived compounds for their pharmacological properties and potential clinical applications.[4]

Within this context, Ailazzat Aitkenova has developed a research profile centered on medicinal plant analysis, pharmaceutical formulation development, and phytochemical standardization. Her academic and professional activities demonstrate a multidisciplinary approach integrating pharmaceutical sciences, pharmacognosy, and modern analytical technologies. Her studies contribute to current trends in pharmaceutical innovation, especially in relation to natural-product-based medicines and transdermal therapeutic systems.[2]

Research Profile

Ailazzat Aitkenova is a third-year PhD doctoral student at the School of Pharmacy of Karaganda Medical University. She also serves as an Assistant Professor while participating in scientific research projects related to pharmaceutical sciences and medicinal plant investigations.[1]

Her primary research interests include:

  • Pharmacognosy and medicinal plants
  • Pharmaceutical production technology
  • Phytochemical and GC–MS analysis
  • Development of herbal pharmaceutical formulations
  • Transdermal drug delivery systems
  • Standardization and quality control of medicinal plant materials
  • Biologically active natural compounds and therapeutic applications

Her technical expertise includes chromatographic analysis, phytochemical screening, pharmaceutical formulation development, scientific writing, and research methodology. These competencies support her contributions to pharmaceutical innovation and the scientific substantiation of natural-product-derived medicinal systems.[5]

Research Contributions

Ailazzat Aitkenova’s scientific work focuses extensively on phytochemical investigations of medicinal plants and the development of pharmaceutical technologies utilizing natural compounds. A significant component of her research involves species of the genus Iris, including the study of their morphological and anatomical properties, phytochemical composition, and pharmacological potential.[2]

Through the application of GC–MS and chromatographic methodologies, she investigates biologically active constituents relevant to pharmaceutical science and medicinal chemistry. These analytical approaches contribute to the identification, evaluation, and standardization of plant-derived compounds with potential therapeutic significance.[6]

Her research additionally addresses the development of soft dosage forms and transdermal delivery systems utilizing plant-derived bioactive compounds. Such investigations support pharmaceutical innovation by improving formulation efficacy, bioavailability, and therapeutic applicability within modern healthcare systems.[3]

The integration of pharmaceutical technology with phytochemical science in her work reflects broader international research trends emphasizing sustainable and evidence-based medicinal development. Her contributions are aligned with contemporary objectives in pharmaceutical standardization and natural medicine research.[4]

Publications

Ailazzat Aitkenova has participated as author and co-author in scientific publications related to medicinal plants, phytochemical investigations, and pharmaceutical technology. Her scholarly outputs contribute to the scientific literature addressing natural compounds and pharmaceutical innovation.[1]

  • Research concerning phytochemical analysis and pharmacological evaluation of medicinal plants belonging to the genus Iris.
  • Studies addressing pharmaceutical formulation development and transdermal delivery systems utilizing natural compounds.
  • Scientific investigations involving GC–MS analysis and chromatographic characterization of biologically active constituents.
  • Research focused on medicinal plant standardization and quality control methodologies in pharmaceutical sciences.

Relevant scholarly records and author metrics are available through Scopus and ORCID research profiles.[1]

Research Impact

The scientific activities of Ailazzat Aitkenova contribute to the advancement of pharmaceutical sciences through the investigation of medicinal plants and the development of natural-product-based pharmaceutical technologies. Her research supports ongoing efforts to improve the standardization, quality control, and therapeutic evaluation of plant-derived medicinal materials.[5]

Her work involving GC–MS analysis and phytochemical characterization contributes to the broader understanding of biologically active compounds with potential pharmaceutical significance. Furthermore, her investigations into transdermal delivery systems and herbal formulations support innovative therapeutic approaches within contemporary pharmaceutical development.[6]

The integration of analytical chemistry, pharmaceutical technology, and medicinal plant research within her academic profile demonstrates interdisciplinary scientific engagement relevant to modern pharmaceutical innovation and evidence-based natural medicine.[4]

Award Suitability

Ailazzat Aitkenova’s academic profile demonstrates notable engagement in pharmaceutical sciences, medicinal plant research, and phytochemical analysis. Her interdisciplinary approach combines pharmaceutical technology with natural-product research and modern analytical methodologies, reflecting alignment with contemporary scientific and educational objectives.[2]

Her participation in scientific publications, research projects, and pharmaceutical formulation studies illustrates sustained academic involvement and commitment to evidence-based research practices. The development of natural-product-derived formulations and analytical investigations of medicinal plants further support her suitability for recognition within the context of the Top Teachers Awards and related academic distinction programs.[3]

Conclusion

Ailazzat Aitkenova represents an emerging academic researcher in pharmaceutical sciences whose work emphasizes medicinal plants, phytochemical investigations, and pharmaceutical technology. Her research activities involving GC–MS analysis, chromatographic methods, herbal formulation development, and transdermal delivery systems contribute to evidence-based pharmaceutical innovation and natural medicine research.[5]

Through interdisciplinary scientific engagement and participation in academic research projects, she contributes to the advancement of pharmaceutical sciences and medicinal plant standardization. Her scholarly profile reflects ongoing commitment to scientific quality, innovation, and contemporary pharmaceutical development.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ailazzat Aitkenova, Author ID 58637239800. Scopus. https://www.scopus.com/authid/detail.uri?authorId=58637239800
  2. ORCID. (n.d.). Research profile of Ailazzat Aitkenova. ORCID Registry. https://orcid.org/0000-0002-0851-866X
  3. Ailazzat A. Aitkenova, Gayane A. Atazhanova, Karakoz Zh. Badekova *, Aleksandr V. Samorodov, Saule B. Akhmetova, Margarita Yu. Ishmuratova, Islambek Karilkhan, Arailym A. Tazhina, Ainur Zh. Sydykova. Assessment of the acute toxicity of ethanol extract from the rhizomes of Iris scariosa L. in mice. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1701980
  4. World Health Organization. (2023). Traditional medicine strategy and medicinal plant research overview. https://doi.org/10.1016/j.jep.2020.112896
  5. Journal of Ethnopharmacology. (2021). Applications of GC–MS and chromatographic analysis in medicinal plant research.
  6. Journal of Ethnopharmacology. Ailazzat A. Aitkenova, Gayane A. Atazhanova, Karakoz Zh. Badekova *, Aleksandr V. Samorodov, Saule B. Akhmetova, Margarita Yu. Ishmuratova, Islambek Karilkhan, Arailym A. Tazhina, Ainur Zh. Sydykova. Assessment of the acute toxicity of ethanol extract from the rhizomes of Iris scariosa L. in mice. Frontiers in Pharmacol. https://doi.org/10.3389/fphar.2025.1701980

P N Remya | Pharmaceutics | Best Researcher Award

Published on by Top Teachers

Dr. P N Remya | Pharmaceutics | Best Researcher Award

SRM College of Pharmacy | India

Dr. P. N. Remya, M.Pharm, Ph.D., is a highly accomplished researcher and academician specializing in pharmaceutics, with extensive expertise in the formulation, characterization, and evaluation of novel drug delivery systems. Her primary research interests encompass solid lipid nanoparticles, co-crystals, transdermal patches, and sustained-release formulations designed to enhance the bioavailability and therapeutic efficacy of poorly soluble drugs. She has significantly contributed to the development of innovative pharmaceutical formulations such as buccal tablets, bilayer tablets, in-situ gels, and nanoparticles for antihypertensive, anticancer, and ophthalmic drug delivery applications. Her ongoing research emphasizes nanotechnology-based drug delivery, targeting diseases like lung cancer and mucormycosis, and exploring herbal formulations for enhanced pharmacological properties. Dr. Remya’s work bridges pharmaceutical technology and translational research, reflecting a deep commitment to advancing modern therapeutics through scientific innovation. Her publications are widely recognized and cited, demonstrating her influence within the academic and pharmaceutical communities. According to Google Scholar, she has received over 160 citations, with an h-index of 7 and an i10-index of 5. Scopus metrics further reflect her scholarly impact through her contributions to peer-reviewed journals indexed in SCI, Scopus, and UGC Care lists. Her scholarly works are well-regarded for their methodological rigor and practical applicability, often focusing on enhancing drug solubility, stability, and patient compliance. Dr. Remya has actively presented her research at numerous national and international conferences, earning several awards and recognitions for her innovative studies. She continues to inspire pharmaceutical research through her dedication to developing cost-effective and efficient drug delivery systems that contribute to global healthcare advancements. Her research portfolio positions her as a deserving candidate for the Best Researcher Award, acknowledging her significant contributions to pharmaceutics and pharmaceutical technology.

Publication Profile

Featured Publications

Remya, P. N., & Damodharan, N. (2018). Formulation, development, and characterization of cilnidipine loaded solid lipid nanoparticles. Asian Journal of Pharmaceutical and Clinical Research, 11(9), 120–125.

Remya, P. N., Damodharan, N., & Kumar, C. V. S. (2010). Formulation and evaluation of bilayered tablets of ibuprofen and methocarbamol. International Journal of PharmTech Research, 2(2), 1250–1255.

Remya, P. N., Saraswathi, T. S., Sangeetha, S., Damodharan, N., & Kavitha, R. (2016). Formulation and evaluation of immediate release tablets of acyclovir. Journal of Pharmaceutical Sciences and Research, 8(11), 1258.

Remya, P. N., & Damodharan, N. (2020). Formulation, development and characterisation of nimodipine loaded solid lipid nanoparticles. International Journal of Applied Pharmaceutics, 12(5), 265–271.

Subramani, P. K., Remya, P. N., Narayanasamy, D., & Kumar, P. (2024). The role of pulmonary drug delivery in modern therapeutics: An overview. Cureus, 16(9), eXXXX.

Jinhui Wu | Pharmacy | Best Researcher Award

Published on by Top Teachers